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LETTER TO THE EDITOR Open Access
Clinical pathways for inborn errors of metabolism:
warranted and feasible
Serwet Demirdas1†, Imke N van Kessel1†, Marjolein J Korndewal1, Carla EM Hollak2, Hanka Meutgeert3, Anja Klaren3,
Margreet van Rijn4, Francjan J van Spronsen4, Annet M Bosch1* and Dutch working Group
Abstract
Inborn errors of metabolism (IEMs) are known for their low prevalence and multidisciplinary care mostly founded
on expert opinion. Clinical pathways are multidisciplinary tools to organise care which provide a clear route to the
best care and improve communication. In 2010 the Dutch Society for Children and Adults with an Inborn Error of
Metabolism (VKS) initiated development of clinical pathways for inborn errors of metabolism. In this letter to the
editor we describe why it is warranted to develop clinical pathways for IEMs and shortly discuss the process of
development for these pathways in the Netherlands.
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Introduction
Inborn errors of metabolism (IEMs) are known for their
low prevalence and chronic need of medical care. Care
provided is multidisciplinary and often based on expert
opinion. In recent years, excellent guidelines on meta-
bolic disorders have been developed and published [1-5].
In 2010 the Dutch Society for Children and Adults with
an Inborn Error of Metabolism (VKS) initiated develop-
ment of clinical pathways for 20 IEMs, with separate
versions for professionals and patients. This letter
discusses why clinical pathways for IEMs are warranted
and feasible.
Background
Clinical pathways are a tool for multidisciplinary deci-
sion making and organization of care processes for well
defined groups of patients [6]. Often they are based on
guidelines [7-9]. Pathways optimize clinical outcomes
whilst maximizing clinical efficiency [10]. For example,
they describe which actions should be taken, when, and
by whom [11]. It has been demonstrated that use of
pathways decreases duration of inpatient care, increases
interdisciplinary communication, enhances patient
knowledge and self awareness, leads to significant better
coordination of care and reduces costs [7,9,12-14].
Clinical pathways can be valuable for patients with
IEMs. Firstly, low prevalence of IEMs leads to limited
knowledge about best practice. In the absence of robust
evidence, expert opinion and outcomes of clinical stud-
ies can support the establishment of a clinical pathway
[12]. When frequently updated, it presents a reference to
latest state of art in care [15,16] and provides guidance
for further research. Secondly, a multidisciplinary ap-
proach is of great importance. The complexity of multi-
disciplinary care may lead to delay of care, overuse of
diagnostics or therapy and miscommunication between
caregivers [7]. Multidisciplinary cooperation using a clin-
ical pathway will improve communication and provide a
clear route to best care, based on consensus. Thirdly,
clinical pathways may improve care for patients when
used in local hospitals, while the physicians in academic
referral centers can serve as consultants. Finally, clinical
pathways become more important as transition to adult
care increases [17], leading to more active participation
of patients in their treatment.
The design of clinical pathways for inborn errors of
metabolism
Design and consensus
The initiative for development of clinical pathways was
taken by the patient society (VKS). Dutch expert
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pediatricians, internists and dieticians for each specific
disorder in cooperation with the VKS created the
pathways. The final version was discussed in a national
consensus meeting. Separate versions were made for
professionals and for patients, presenting the Dutch con-
sensus. All advice is substantiated by a level of evidence
[18], according to the scoring system of the Dutch Insti-
tute for Healthcare Improvement CBO. Level 1: 1 system-
atic review or 2 independent high quality randomized
controlled trials (RCTs); level 2: 2 independent moderate
RCTs or comparative trials; Level 3: 1 RCT, comparative
or non-comparative trial; Level 4: expert opinion [19].
Clinical pathway for professionals
The first section of the version for professionals comprises
a general introduction and concise strategy for diagnostics
and treatment. Second and third sections contain more
specific guidance for treatment and follow up in childhood
and adulthood.
The pathways include responsibilities for each profes-
sional, advised frequency for outpatient visits and
laboratory studies, and recommendations on follow up
of known complications of the disorder. In the pediatric
pathway one chapter is dedicated to transition from
pediatric to adult care.
In the pathways all advice is substantiated by a level of
evidence. Evidence levels 3 and 4 were common. Level 1
was rarely available and mostly resulted from trials
evaluating a novel pharmaceutical agent. Most advice
was therefore founded on expert opinion and trials of
moderate quality.
Clinical pathway for patients
The first section of the patient version contains general
information on the disorder and its treatment. The sec-
ond and third sections address treatment and follow up
in childhood and adulthood. The purpose of the pathway
for patients is to provide insight into current consensus
of best practice and an overview of all professionals
involved. It provides clarity on responsibilities, including
that of the patient/parents who take a prominent place
in the treatment team.
For active patient participation, patients must be
provided evidence based information in an appropriate
and comprehensible form [20]. The fact that the patient
versions are based on the professional pathway ensures
that they are in accordance with available evidence, and
comprehensibility is secured by cooperation with the
VKS.
We demonstrated that development of clinical
pathways for IEMs is feasible and we were able to reach
national consensus. At this time, Dutch pathways are
publically available for 20 diseases including urea cycle
defects, organic acidurias, mitochondrial fatty acid
oxidation disorders, galactosemia, phenylketonuria,
tyrosinemia, glycogen storage disorders, congenital dis-
order of glycosylation type 1a, and Niemann Pick type
c [21].
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